Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc (NY: OGEN )

2.020 -0.020 (-0.98%)
Official Closing Price Updated: 8:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,943
Open 2.030
Bid (Size) 1.920 (90)
Ask (Size) 2.070 (2)
Prev. Close 2.040
Today's Range 1.980 - 2.130
52wk Range 1.000 - 7.740
Shares Outstanding 4,480,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
Via Benzinga
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga

Performance

YTD
-70.21%
-70.21%
1 Month
+85.32%
+85.32%
3 Month
-38.41%
-38.41%
6 Month
-43.89%
-43.89%
1 Year
-32.89%
-32.89%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
OGEN Stock Earnings: Oragenics Reported Results for Q1 2024
Via InvestorPlace
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
Via InvestorPlace
Why Is Integral Ad Science (IAS) Stock Down 29% Today?
Via InvestorPlace
Why Is Oragenics (OGEN) Stock Down 45% Today?
Via InvestorPlace
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Oragenics Announces Pricing of Public Offering
From Oragenics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.